OKUR insider trading
NasdaqGM HealthcareOnKure Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Company website: onkuretherapeutics.com
OKUR insider activity at a glance
FilingIQ tracks 34 insider transactions for OKUR in filings since Oct 8, 2024. The most recent transaction is dated Sep 21, 2026.
Across the full history, 2 open-market purchases
and 18 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on OKUR insider trades is 62.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest OKUR Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for OKUR?
- FilingIQ tracks 34 Form 4 insider transactions for OKUR (OnKure Therapeutics, Inc.), covering filings from Oct 8, 2024 onwards. 2 of those are dated within the last 90 days.
- Are OKUR insiders net buyers or net sellers?
- Across the full Form 4 history for OKUR, 2 transactions (6%) were open-market purchases and 18 (53%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does OKUR insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is OKUR in?
- OnKure Therapeutics, Inc. (OKUR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $54.42M.
Methodology & sources
Every OKUR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.